JNB Advisors »

Vertex Pharmaceuticals Incorporated shares owned by JNB Advisors

Quarter-by-quarter ownership of Vertex Pharmaceuticals Incorporated (VRTX) shares owned by JNB Advisors from 13F filings

Historical chart of JNB Advisors investment in Vertex Pharmaceuticals Incorporated

Tip: Access up to 7 years of quarterly data

All positions including Vertex Pharmaceuticals Incorporated held by JNB Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Vertex Pharmaceuticals Incorporated by JNB Advisors

Quarter filed Position value Share count Share price at filing
2024-03-31 $973k 2.3k 418.01
2023-12-31 $911k 2.2k 406.89
2023-09-30 $713k 2.1k 347.74
2023-06-30 $602k 1.7k 351.91
2023-03-31 $357k 1.1k 315.07
2022-12-31 $237k 820 288.78
2022-09-30 $232k 802 289.28

More positions owned by JNB Advisors

Ishares Core S&p 500 Etf Etf (IVV)
Ishares Russell 1000 Growth Etf Etf (IWF)
Spdr S&p 500 Etf Trust Etf (SPY)
Technology Select Sector Spdr Fund Etf (XLK)
Nvidia Corporation Stock (NVDA)
Ishares Core S&p Small Cap Etf Etf (IJR)
Ishares Core S&p Mid-cap Etf Etf (IJH)
Apple Stock (AAPL)
Microsoft Corp Stock (MSFT)
Ishares Russell 1000 Value Etf Etf (IWD)
Health Care Select Sector Spdr Fund Etf (XLV)
Vanguard Total Stock Market Etf Etf (VTI)
Financial Select Sector Spdr Fund Etf (XLF)
Jpmorgan Equity Premium Income Fund Jpmorgan Equity Premium Income Fund Etf (JEPI)
Consumer Discretionary Select Sector Spdr Fund Etf (XLY)

View all positions for JNB Advisors

Top funds holding Vertex Pharmaceuticals Incorporated

Vanguard Group
Alliancebernstein
T. Rowe Price Associates
Jpmorgan Chase & Co
Wellington Management Company
Jennison Associates
Massachusetts Financial Services
Norges Bank Investment Management
Amundi
Bank of America Corporation
Ubs Global Asset Management Americas
ClearBridge Advisors
Legal & General Group
Henderson Group
Bank of New York Mellon

View all funds holding Vertex Pharmaceuticals Incorporated